Dan L. Duncan Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Dan L. Duncan Comprehensive Cancer Center


Baylor Awarded CPRIT Grants to Support Cancer Research

August 26, 2019

Baylor College of Medicine has been awarded more than $17.4 million by the Cancer Prevention & Research Institute of Texas to support new cancer research and programs, core facilities and recruitment of new faculty.

Dr. Navai on Treatment Options in Relapsed/Refractory Sarcoma

May 17, 2019

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

Dr. Smaglo Discusses the FDA Approval of TAS-102 for Gastric/GEJ Cancer

February 26, 2019

Brandon G. Smaglo, MD, FACP, assistant professor of internal medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the FDA approval of TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

October 02, 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.